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Abstract: Bacterial infection of the lower respiratory tract in chronic obstructive pulmonary 
disease (COPD) patients is common both in stable patients and during acute exacerbations. The 
most frequent bacteria detected in COPD patients is Haemophilus influenzae, and it appears 
this organism is uniquely adapted to exploit immune deficiencies associated with COPD and to 
establish persistent infection in the lower respiratory tract. The presence of bacteria in the lower 
respiratory tract in stable COPD is termed colonization; however, there is increasing evidence 
that this is not an innocuous phenomenon but is associated with airway inflammation, increased 
symptoms, and increased risk for exacerbations. In this review, we discuss host immunity that 
offers protection against H. influenzae and how disturbance of these mechanisms, combined 
with pathogen mechanisms of immune evasion, promote persistence of H. influenzae in the 
lower airways in COPD. In addition, we examine the role of H. influenzae in COPD exacerba-
tions, as well as interactions between H. influenzae and respiratory virus infections, and review 
the role of treatments and their effect on COPD outcomes. This review focuses predominantly 
on data derived from human studies but will refer to animal studies where they contribute to 
understanding the disease in humans.
Keywords: chronic obstructive pulmonary disease, Haemophilus influenzae, nontypeable 
Haemophilus influenzae, respiratory viruses, vaccination
COPD overview
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and 
is the fourth leading cause of mortality worldwide.1 Conservative estimates sug-
gest a 10% prevalence in the general population, but among heavy smokers, this 
figure increases to almost 50%.2 The clinical course of COPD is characterized by a 
progressive decline in lung function, accompanied by worsening exercise tolerance 
and health status. The pathological hallmark of COPD is an abnormal inflammatory 
response in the airways and alveoli. The principal abnormalities in airways are the 
presence of an inflammatory cellular infiltrate and remodeling that thickens the airway 
wall, thereby reducing the airway diameter and increasing resistance to flow.2 In the 
lung parenchyma, COPD is characterized by prominent inflammatory infiltrates in the 
alveolar walls, destruction of alveoli, and enlargement of air spaces. Cigarette smoking 
is a predominant etiological factor in the development of COPD, but other factors such 
as burning biomass fuels for cooking and heating are important causes, particularly 
in developing countries. Although exposure to cigarette smoke/biomass smoke is 
required for the development of COPD, disease progression and airway inflammation 
persist even after smoking cessation.3 Therefore, other factors contribute to persistence 
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of inflammation and progression of the disease. One such 
factor is respiratory infection, with both bacterial and viral 
infections implicated in contributing to the pathogenesis of 
COPD.4,5 Bacteria are commonly detected in COPD, with 
the most common organism isolated being Haemophilus 
influenzae in most studies. The chronic clinical course of 
COPD is punctuated by periods of increased symptoms, 
termed acute exacerbations,6 which have both short- and 
long-term adverse effects in COPD patients. They have 
immediate effects resulting in considerable morbidity and 
mortality in COPD and are a major cause of excess health 
care costs, as they often result in unscheduled health care vis-
its, treatment costs, and hospitalizations. Exacerbations also 
have long-term effects, as frequent exacerbations are associ-
ated with more rapid decline in lung function, airway and 
systemic inflammation, and impaired quality of life.7–9 
Approximately half of all COPD exacerbations are associ-
ated with bacterial infections, and as is the case in stable 
COPD, the most common bacteria detected is H. influenzae.10 
Therefore, H. influenzae may have a major pathogenic role 
both in stable COPD and in COPD exacerbations and has 
been the focus of much research interest.
H. influenzae: bacteriology
H. influenzae is a pleomorphic Gram-negative coccobacillus 
that is isolated exclusively from humans, predominantly from 
the respiratory tract. It is a member of the Pasteurellaceae 
family and is capable of growing either aerobically or 
anaerobically,11 and strains are divided into two groups 
on the basis of the presence of a polysaccharide capsule. 
 Encapsulated strains are reactive with typing antisera 
(typeable), whereas unencapsulated strains are nonreac-
tive (nontypeable H. influenzae [NTHi]). Six encapsulated 
serotypes (a–f) have been identified and account for the 
majority of invasive Haemophilus infections such as sep-
ticemia, pneumonia, and meningitis. NTHi, in contrast, 
rarely causes invasive disease but commonly colonizes the 
upper respiratory tract and can cause mucosal infections in 
both children and adults. The vast majority of Haemophilus 
strains isolated from the respiratory tract in COPD patients 
are NTHi. H. influenzae is a common commensal of the 
upper respiratory tract, with 20% of children colonized in 
the first year of life and up to 50% colonized by age 5 years.12 
Disease caused by NTHi is predominantly by contiguous 
spread from the nasopharynx to adjacent structures such as 
sinuses, the middle ear, and trachea. In contrast to the fre-
quent detection of H. influenzae in the upper respiratory tract, 
lower respiratory tract colonization appears rare in healthy 
individuals. In 70 healthy subjects from six different studies 
undergoing bronchoscopy, H. influenzae was detected in 
only 4%.13 Two subsequent studies that were not included in 
this analysis have been published more recently. In the first, 
H. influenzae was not detected in any of 26 healthy individu-
als undergoing bronchoscopy during anesthesia for elective 
surgery.14 In the second, H. influenzae was isolated in two 
(13.3%) of 15 healthy subjects who had never smoked, but 
in zero of 20 exsmokers.15 Therefore, from these results, the 
true prevalence of lower respiratory tract colonization with 
H. influenzae in healthy individuals is unclear, but it is undoubt-
edly lower than that in the upper respiratory tract. These 
studies were small, and therefore it is difficult to draw con-
clusions from them regarding the prevalence of H. influenzae 
colonization in the general population. Discrepancies in 
detection rates between studies are likely to be related to 
differences in characteristics of the populations studied, such 
as age, sex, smoking history, and so on, and further studies 
with greater numbers of participants are required.
Methods to detect H. influenzae
For many years, the standard method for detection of 
H. influenzae in respiratory samples was growth on 
culture plates and identif ication using morphological 
characteristics and growth requirements. However, cul-
ture has a number of drawbacks, including difficulty in 
distinguishing H. influenzae from other bacterial species, 
such as Haemophilus haemolyticus and Haemophilus 
parainfluenzae, as well as low sensitivity. H. influenzae 
possesses the ability to persist in biofilms and within host 
cells, and organisms in these niches may not be detected 
using culture of airway samples such as sputum, bronchial 
wash, and bronchoalveolar lavage.16 Culture-independent 
techniques based on detection and amplification of nucleic 
acid sequences using polymerase chain reaction (PCR) have 
been developed during the past 2 decades to detect pathogens 
such as H. influenzae. Protein D is a highly conserved surface 
lipoprotein present in all encapsulated and nonencapsulated 
H. influenzae strains,17 making its gene (hpd) an attractive 
target for the development of a PCR assay. An hpd real-time 
PCR assay can detect both encapsulated H. influenzae and 
NTHi strains with high sensitivity and specificity.18 Studies 
comparing bacterial detection rates using culture and PCR 
have consistently demonstrated greater sensitivity with PCR. 
Detection rates of H. influenzae in nasopharyngeal swabs 
collected from healthy individuals are 2.5–3 times greater 
with PCR compared with culture.19,20 As will be described 
in the following section, this has also been reported in 
International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1121
Haemophilus influenzae in COPD
COPD patients. However even with PCR, distinguishing 
H. influenzae from other species such as H. haemolyticus 
can be difficult,21 and more sophisticated techniques such as 
proteomic profiling may be required.22 More recently, newer 
techniques have been developed based on the sequenc-
ing of the 16S gene encoding bacterial ribosomal RNA. 
The 16S gene contains invariant regions used for priming 
the sequencing reaction and variable regions that permit 
genus- and species-level identification. High-throughput 
sequencing and sorting of the amplicons generated enables 
the identification of entire microbial communities. These 
techniques have revealed the presence of a respiratory 
“microbiome,” even in the respiratory tracts of healthy indi-
viduals, and overturned the previous dogma that the lower 
airways are sterile in health.23 Initial studies have revealed 
that the genus Proteobacteria that includes Haemophilus 
is overrepresented in the airways of subjects with asthma 
and COPD compared with in healthy individuals.24 Further 
studies of the respiratory microbiome are likely to radically 
change our understanding of the role of bacteria such as 
H. influenzae in both health and disease.
The epidemiology of H. influenzae  
in COPD
It is well established that bacteria are often present in the 
lower airways in patients with stable COPD, although 
colonization rates vary between different studies and are 
affected by factors such as disease severity, treatments 
used, and sampling methods used. A pooled analysis of 
studies using bronchoscopic sampling reported that poten-
tially pathogenic organisms were present in 29% of stable 
COPD patients,13 and studies using sputum have reported 
that potentially pathogenic organisms are present in up to 
half of COPD patients.25–27 The most common organisms 
detected in COPD patients are consistently H. influenzae, 
Streptococcus pneumoniae, and Moraxella catarrhalis, 
with H. influenzae accounting for around half of all isolates 
in the airways of COPD patients.13,25–27 However, the true 
prevalence of infection with H. influenzae in COPD may 
be underestimated by studies using culture for bacterial 
detection. In a longitudinal study over the course of 7 years, 
Murphy et al reported frequent episodes when sputum 
cultures were negative that were preceded and followed by 
positive cultures with the same strains of H. influenzae, and 
strain-specific H. influenzae DNA was detected in some of 
the sputum samples that had negative cultures.28 Other studies 
using PCR have confirmed higher detection rates compared 
with culture alone in COPD,29–31 with H. influenzae detected 
in 60% of sputum samples using PCR compared with only 
30% using culture.31
Bacteria can be detected in sputum in 50%–60% 
of COPD patients during acute exacerbations, and 
H.  influenzae is consistently among the most common bac-
teria reported.10,13,32 As discussed previously, even this may 
be an underestimate because of the limitations of culture. In 
a study of 15 chronic bronchitis patients with acute respira-
tory failure, NTHi was detected in only one bronchial wash 
specimen, whereas using in situ hybridization, intracellular 
NTHi was present in 13 (86.7%) of 15 bronchial biopsies.14 
Sequencing studies have revealed that Proteobacteria are 
a key component of the respiratory microbiome in COPD 
exacerbations.33, 34
Therefore, although it is clear that lower respiratory 
tract infection with H. influenzae is much more prevalent in 
COPD patients compared with healthy individuals, the exact 
prevalence remains to be determined and is highly dependent 
on the diagnostic method used.
Host immunity and immune evasion 
in H. influenzae infection
H. influenzae commonly colonizes the nasopharynx and 
causes upper respiratory tract disease in healthy individu-
als, but infection of the lower airways is rare because of 
host immune responses that prevent spread to the lower 
respiratory tract. In contrast, H. influenzae is commonly 
found in the lower airways of patients with COPD, imply-
ing that mucosal host immune mechanisms are impaired. 
H. influenzae possesses a number of mechanisms to avoid 
or neutralize host immune responses, and therefore it is 
likely that the combination of pathogen immune evasion and 
impaired host immunity combine to promote lower airway 
infection in COPD.
Host immunity to H. influenzae  
in healthy individuals
Structural components
The structural integrity of the respiratory tract is vital 
to preventing infection with inhaled microorganisms. 
Important mechanisms including an intact respiratory 
epithelium, mucus production, and mucociliary clearance 
via the action of cilia and cough act to prevent infection with 
respiratory pathogens such as H. influenzae.4,11 The impor-
tance of these mechanisms in host defense is highlighted 
by high rates of H. influenzae infection in conditions such 
as cystic fibrosis35 and immotile cilia syndromes36 that are 
characterized by abnormal mucociliary function.
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Cellular immunity
Immune cells such as neutrophils and alveolar macrophages 
are present in large numbers in the airways and consti-
tute a first line of defense against respiratory pathogens. 
Macrophages recognize microorganisms via the presence 
of surface receptors such as toll-like receptors leading to 
phagocytosis, microbicidal killing, and initiation of immune 
responses.11 A key component of the NTHi cell wall is lipo-
oligosaccharide, which is recognized by toll-like receptor 4, 
leading to macrophage activation and phagocytosis,37 and the 
membrane protein P2, recognized by toll-like receptor 2.38,39 
P6 is a specific trigger of macrophage activation, with secre-
tion of interleukin 8 (IL-8) and tumor necrosis factor α being 
key effectors of P6-induced macrophage responses.40
Complement and immunoglobulin A
The complement system is an essential part of the innate 
immune system, and activation of complement results in 
protein activation and deposition on the surface of patho-
gens, resulting in opsonization and phagocytosis. Invading 
pathogens activate complement either through antibody 
binding (classical pathway) or spontaneously via the 
alternative pathway.41 Although complement is not present 
in the healthy human respiratory tract, after infection and 
inflammation, the permeability of the mucosa increases 
and plasma, including complement proteins, enters the 
airway lumen.42,43 Immunoglobulin A (IgA) is the main 
element of the humoral immune response that provides 
protection against microbial antigens at mucosal surfaces, 
including the lung. Mucosal IgA can bind to bacteria and 
prevent mucosal attachment and facilitate cytotoxicity.44 
The importance of complement and IgA in host defense 
against pathogens is illustrated by the increased suscep-
tibility to bacterial infections, including H. influenzae, 
seen in patients with complement def iciencies and 
hypogammaglobulinemia.45,46
Adaptive immunity
The adaptive immune response consists of humoral (B-cell-
mediated) and cellular (T-cell-mediated) immunity.4,47 
Hypogammaglobulinemia is a risk factor for systemic infec-
tion by NTHi, illustrating the importance of antibodies.48 
T-helper cells and cytotoxic T lymphocytes contribute by 
producing interferon γ,4 which enhances the macrophage-
induced killing of NTHi.49 Cytotoxic T cells and natural 
killer cells may be particularly important in the control of 
intracellular pathogens,50 and there is evidence that impaired 
T-helper responses to H. influenzae contribute to the failure 
to eradicate intracellular infection,49 resulting in chronic 
airway infection.47
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Figure 1 Interactions between chronic obstructive pulmonary disease (COPD), virus infection, and persistent infection with Haemophilus influenzae. Structural changes in 
the airways and impaired innate and acquired immunity in COPD are exploited by H. influenzae, leading to failure to eradicate the organism and persistent infection. virus 
infections may also cause epithelial damage and immune suppression and may favor persistent infection. Persistent infection with H. influenzae enhances airway inflammation 
and may contribute to disease progression in COPD.
Abbreviations: ↑, increased; ↓, decreased.
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Mechanisms of immune evasion  
by H. influenzae
Phase variation and antigenic change
H. influenzae has the ability to lose or gain cell structures, 
thereby allowing it to evade host immune responses, par-
ticularly antibody-mediated immunity. This property is 
called phase variation and has been reported for a number of 
different components of H. influenzae, including adhesins, 
pili, and lipooligosaccharide.51,52 Furthermore, some strains 
of H. influenzae undergo permanent changes in the amino 
acid sequences of important immunogenic surface proteins 
such as P2 and P5 in a manner reminiscent of antigenic drift 
in influenza viruses.53 There is evidence that phase variation 
may contribute to persistent infection in COPD, as it has been 
reported that serial isolates of H. influenzae from patients 
with COPD demonstrate decreased levels of HMW1 and 
HMW2 in association with persistence.54
Intracellular growth/biofilms
H. influenzae exhibits a number of different growth strategies 
that promote survival, including intracellular growth and the 
formation of biofilms.52 Biofilms are microbial communities 
that are encased within a matrix and can be found in a num-
ber of environments, including the human respiratory tract. 
Biofilms are believed to confer protection from a number 
of immune mechanisms such as antimicrobial peptides and 
antibodies, as well as from antibiotics, thereby promoting 
survival and persistence. There is evidence from both human 
studies and animal models that H. influenzae forms biofilms, 
which is likely to be an important mechanism in promot-
ing persistent infection in the human respiratory tract.55–58 
Although H. influenzae is predominantly an extracellular 
pathogen, there is evidence it is able to enter cells of the 
respiratory tract. H. influenzae has been detected in epithelial 
cells,59,60 adenoidal tissue,61,62 and monocytes/macrophages.63 
As is the case for biofilm formation, intracellular growth 
may offer H. influenzae protection from antibody-mediated 
immune responses and antibiotics, and therefore may be 
another important mechanism of persistent infection.64 As 
discussed previously, both biofilms and intracellular growth 
may also contribute to underdetection of H. influenzae using 
sputum culture.
Complement/IgA
Complement and IgA are important mechanisms of host pro-
tection against H. influenzae. Some strains of H. influenzae 
demonstrate reduced susceptibility to complement, and 
although the exact mechanisms of this are unknown, a number 
of factors including lipooligosaccharide and surface proteins 
P2 and P5 are believed to contribute.41 In addition, it has been 
demonstrated that NTHi can acquire host complement inhibi-
tors such as vitronectin,65,66 and factor H.67 NTHi can also 
secrete proteases that cleave the main IgA subclass IgA1,68 
thus offering protection against  IgA-mediated cytotoxicity.
Metabolic adaptations
In addition to changes to structural components, organisms 
in the human respiratory tract may undergo adaptations in 
metabolic pathways to survive in a hostile environment with 
limited nutrients, low pH, and high levels of reactive oxygen 
species. Such adaptations adopted by H. influenzae include 
production of urease,69 antioxidants,70 and proteins involved 
in iron and heme metabolism.71 There is evidence that upregu-
lation of these metabolic pathways is related to the ability of 
NTHi strains to survive in the respiratory tract.72–74
Mechanisms of H. influenzae  
infection in COPD
There are a number of structural and functional changes in the 
airways of COPD patients that compromise host immunity to 
respiratory pathogens. H. influenzae has developed a number 
of mechanisms to evade host immune responses, many of 
which are already impaired in COPD. Therefore, among 
respiratory pathogens, H. influenzae appears to be uniquely 
adapted to exploit the already-impaired host immunity in 
COPD and establish persistent infection.
Bacterial adhesion
The first step in establishing infection in the respiratory tract 
by a pathogen is adhesion to the respiratory epithelium. 
H. influenzae possesses a number of cell surface proteins 
and structures that facilitate adhesion to respiratory mucosal 
surfaces. These include the presence of pili (rodlike projections 
present on a small subset of strains75) and a number of surface 
proteins that facilitate adhesion. The membrane proteins P2 
and P5 facilitate binding of the bacteria to mucus,38 and the 
adhesins HMW1, HMW2, protein E, and protein F bind to 
epithelial cells and extracellular matrix proteins.76–78 Protein D 
is a highly conserved 42 kDa surface lipoprotein identified in 
all strains of H. influenzae. The activity of protein D as a viru-
lence factor is as a glycerophosphodiesterase that promotes 
adherence of NTHi to airway epithelial cells and internaliza-
tion by macrophages63 and impairs ciliary function.79–81 The 
airways in COPD patients are characterized by damaged 
epithelium, mucous hypersecretion, and reductions in cilia 
numbers and function. Therefore, this combination of exposed 
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extracellular matrix, excess mucus, and impaired mucociliary 
clearance provides an ideal environment for the adhesion and 
subsequent growth of H. influenzae. Strains of H. influenzae 
isolated from COPD patients are more likely to express adhe-
sion molecules such as HMW.82
Cellular and humoral immunity
Inflammatory cells in the airways such as neutrophils and 
macrophages are increased in COPD, which would be 
expected to result in more effective clearance of inhaled 
pathogens. However, the opposite is the case, as the function 
of these immune cells is impaired. Several studies have dem-
onstrated that phagocytosis of H. influenzae and production 
of cytokines by macrophages is impaired in COPD.40,83–86 
Impaired production of cytokines by macrophages in 
response to H. influenzae has been related to exacerbation 
frequency in COPD patients.83 As discussed previously, sur-
vival of H. influenzae has been documented in macrophages87 
and epithelial cells,88 and intracellular H. influenzae is more 
common in patients with chronic bronchitis compared with 
in healthy subjects.14 Therefore, impaired macrophage 
responses to NTHi may promote intracellular survival, but 
further studies are required to prove this conclusively.
In addition to compromised macrophage function, 
T  lymphocyte cell responses to H. influenzae in COPD are 
also impaired.89 Again, this may have clinical implications, as 
robust T-cell responses to the surface P6 lipoprotein are asso-
ciated with a reduced risk for exacerbations.90 A recent paper 
reported that numbers of T regulatory cells are increased in 
COPD patients.91 Moreover T regulatory cells from COPD 
patients suppressed P6-specific T-cell proliferation to a 
greater extent than T regulatory cells from healthy controls; 
therefore, this may be an important mechanism of reduced 
effector T-cell responses to H. influenzae. Variations in anti-
genic components of the organism, including the membrane 
outer proteins P2 and P592, 93 and the immunoglobulin A1 
protease,94 may contribute to immune evasion and reduced 
host immunity.
There is evidence that IgA secretion is impaired in 
COPD95 and that reduced levels of Haemophilus-specific IgA 
may be related to chronic infection with H. influenzae.96,97
Inflammatory responses  
and H. influenzae in stable COPD
The presence of bacteria in the lower respiratory tract in 
stable COPD patients is termed colonization, but there is 
increasing evidence that this is not a benign phenomenon 
but is associated with adverse outcomes. Bacterial infection 
in stable COPD is associated with increased airways and 
systemic inflammation,98 more frequent exacerbations,27 
and poorer health status.15,99 Therefore, chronic infection or 
persistent infection may be more accurate descriptions than 
colonization.100 Whether all bacterial species have adverse 
effects is unknown, as few studies have examined the role 
of specific bacteria such as H. influenzae. Data from animal 
models have suggested that NTHi can induce both inflamma-
tory and structural changes in the lungs. Chronic instillation 
of NTHi in mice induced an inflammatory infiltrate similar to 
that seen in COPD, with increases in inflammatory cytokines 
and cells (neutrophils, macrophages, and CD8+ T cells) and 
airway collagen deposition.101 When exposed to both cigarette 
smoke and NTHi, mice developed structural changes typical 
of COPD, including emphysema, lung inflammation, and 
goblet cell metaplasia in both large and small airways.102
Human studies have reported that H. influenzae is associ-
ated with higher sputum levels of inflammatory mediators 
such as neutrophils, IL-1β, IL-12, IL-8, tumor necrosis factor 
α, and matrix metalloprotease 9.97,98,103,104 Moreover, COPD 
patients colonized with NTHi reported worse health status 
compared with noncolonized patients, and these effects were 
not seen in patients colonized with other bacteria.98 There-
fore, the presence of H. influenzae in the lower airways of 
COPD patients is associated with increased inflammation 
and poorer health status. Whether the increases in inflamma-
tory mediators contribute to long-term structural changes, 
as has been reported in animal studies, is unknown, but it is 
an important area for further research. Further studies also 
are needed to determine the effects of persistent infection 
with H. influenzae on other outcomes such as exacerbations, 
disease progression, and even mortality.
H. influenzae and COPD 
exacerbations
H. influenzae is frequently detected in airway samples col-
lected from COPD patients during exacerbations,10 but this 
does not prove causation, as the organism may have been 
present when the patient was clinically stable. Studies com-
paring bacterial detection in stable and exacerbated patients 
have generally reported higher rates of bacterial infection 
in COPD exacerbations.10,29,105,106 Therefore, H. influenzae 
infection can result in either chronic infection or acute 
exacerbation. The mechanisms that determine the outcome of 
infection are poorly understood but are likely to involve both 
pathogen and host factors.
Exposure to new strains of NTHi to which the host has 
no preexisting immunity is one mechanism that may underlie 
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the occurrence of acute exacerbations. Sethi et al carried out 
molecular typing on bacteria isolated from sputum samples 
from COPD patients collected when stable and during exacer-
bations over the course of 56 months. Isolation of H. influen-
zae using culture alone was not associated with exacerbations, 
but detection of a new strain was associated with increased 
risk for exacerbation.107 An exacerbation was diagnosed in 
33% of visits at which a new bacterial strain was isolated 
compared with 15.4% of visits at which no new strain was 
present. Therefore, the majority of new strain acquisitions 
did not result in exacerbation, and other mechanisms must 
contribute. It was subsequently recognized that some strains 
of H. influenzae were actually H. haemolyticus species.108 
When the results of the study were reanalyzed with the exclu-
sion of H. haemolyticus, the association between acquisition 
of a new strain of H. influenzae and acute exacerbations was 
stronger.108 In another study from this group, an immune 
response to homologous H. influenzae occurred after 61% 
of exacerbations with newly acquired strains compared with 
21.2% of exacerbations with preexisting strains.109
Factors relating to pathogen-related characteristics 
have been less well defined, but one study has reported a 
different genetic profile in strains associated with exacerba-
tions compared with strains associated with asymptomatic 
chronic infection.110 Moreover, strains isolated from COPD 
patients during an exacerbation elicited greater inflammatory 
responses in mice and in vitro models compared with colo-
nizing strains,111 although another study failed to replicate 
these findings.112 Therefore, it is likely there are complex 
interactions between host immunity and the pathogenicity 
of the infecting strain of H. influenzae that determine the 
outcomes of infection.
Respiratory viruses  
and Haemophilus influenzae
Other external factors may influence the interactions between 
host and H. influenzae; one such factor is infection with a 
respiratory virus. A relationship between influenza infection 
and H. influenzae pneumonia has long been recognized,113 
and in fact, H. influenzae derives its name from the origi-
nal mistaken belief that it was the causative organism of 
influenza. Synergism between the two organisms has been 
demonstrated in animal models.114 Respiratory virus infection 
can be detected in up to 40% of COPD exacerbations,115 and 
therefore virus infections in patients with chronic bacterial 
infection and concurrent virus/bacterial coinfections may be 
a relatively common occurrence. Data from in vitro studies 
and animal studies have suggested a number of potential 
mechanisms whereby virus and bacterial infections may 
interact. Mice infected with rhinovirus show impaired 
clearance of NTHi, which is related to impaired production 
of chemokines by both epithelial cells and macrophages 
in response to bacterial infection.116 Impaired chemokine 
responses to bacterial products in macrophages infected 
with rhinovirus have also been reported.117 Virus infection 
may also have effects on the airway epithelium that promote 
bacterial infection. Rhinovirus infection of epithelial cells 
in vitro disrupts the airway epithelial barrier, resulting in 
increased transmigration of NTHi across the epithelial bar-
rier.118 In addition, rhinovirus infection increases expression 
of adhesion molecules on the surface of epithelial cells and 
enhances bacterial adhesion,119,120 and this effect has also 
been reported for other respiratory viruses.121 Whether these 
mechanisms are relevant in vivo is not known. Rhinovirus 
infection did not increase expression of the receptor platelet 
activating receptor in vivo in bronchial biopsies in COPD 
patients.122
Few studies have examined the role of concurrent virus-
bacteria coinfection in COPD exacerbations. Those that 
are available have reported detection rates of between 12% 
and 25%.10,30 A study examining infection with respiratory 
viruses and H. influenzae found evidence of coinfection in 
only 9% of exacerbations.123 Our group has examined the 
relationship between viral and bacterial infections in COPD 
patients, using experimental rhinovirus infection as a model 
of COPD exacerbation.124 In COPD subjects infected with 
rhinovirus, secondary bacterial infections occurred in 60%, 
with H. influenzae the predominant organism (46% of bacte-
rial isolates). The peak of virus infection occurred on day 5 
postinoculation, whereas the peak of bacterial infection 
occurred later, on day 15. Therefore, studies in naturally 
occurring exacerbations in which a sample is collected at 
a single point are likely to underestimate the frequency of 
coinfections, as our data demonstrate that bacterial infection 
occurs up to 10 days after the initial viral infection. This was 
confirmed by two studies that carried out sequential sampling 
during COPD exacerbations. In one study, samples were 
collected at the onset of exacerbation and again 5–7 days 
later.125 In 19% of COPD exacerbations, a virus and bacteria 
were detected at exacerbation onset, but 36% of exacerba-
tions in which a virus was detected on day 1 developed 
bacterial infection in the next 7 days. The commonest virus/
bacteria combination was rhinovirus/H. influenzae; 78% of 
exacerbations in which H. influenzae was detected were pre-
ceded by symptoms of an upper respiratory tract infection. 
In the second study, COPD exacerbations associated with 
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rhinovirus infection had bacteria detected in 73% of second 
samples collected 14 days later.126 Again, H. influenzae was 
the most frequent bacterial isolate. In both experimental124 
and natural infections,106 virus infection is associated with 
higher bacterial loads.
Participants who developed secondary bacterial infection 
after experimental rhinovirus infection had lower airway 
levels of the antimicrobial peptides elafin and secretory 
leukoprotease inhibitor,124 suggesting another mechanism 
whereby virus infections may impair antibacterial immune 
responses.
In the experimental rhinovirus model, no subjects had 
bacteria detected by sputum culture at baseline before 
inoculation with rhinovirus; however, using sequencing 
techniques to analyze the bacterial microbiome, bacterial 
DNA could be detected. We further examined whether virus 
infection had an effect on the respiratory microbiome. After 
virus infection, there was a 16% increase in the number 
of proteobacterial sequences on day 15 postinoculation.33 
Within the Proteobacteria phylum, there was a 21% increase 
in the average relative abundance of H. influenzae. At day 
42 postinoculation, H. influenzae remained elevated com-
pared with baseline, despite no organisms being detected 
by culture at this point. Therefore, this is the first in vivo 
evidence that a virus infection can induce a profound and 
prolonged change in the bacterial microbiome in the lungs 
and that there appears to be a specific interaction between 
rhinovirus and H. influenzae. The subjects included in the 
experimental infection studies had GOLD stage II COPD, 
had negative baseline sputum cultures, were not using 
inhaled cortico steroids, and had few previous exacerba-
tions. In patients with more severe COPD with positive 
sputum cultures, the effect of virus infection on the bacterial 
microbiome may be even more pronounced. This holds out 
the prospect that treating or preventing viral infections may 
also reduce secondary bacterial infections and excessive 
antibiotic use.
Most research has focused on bacterial infections occur-
ring after initial virus infection. However, chronic bacterial 
infection may also influence host responses to respiratory virus 
infections. H. influenzae infection of human epithelial cells 
potentiates cytokine responses and increases virus binding 
after subsequent rhinovirus infection.127 There are as yet no data 
investigating whether chronic bacterial infection influences 
responses to virus infection in vivo in COPD. The presence 
of bacteria in the lower airways is associated with increased 
exacerbations, and increased susceptibility to virus infection 
may be one mechanism mediating this effect, but further 
studies are needed to investigate this. Potential mechanisms 
of interactions between COPD, Haemophilus influenzae and 
respiratory virus infection are summarized in Figure 1.
Therapies
In view of the evidence that persistent H. influenzae 
infection is associated with adverse outcomes in COPD, 
treating H. influenzae holds out the possibility of clinical ben-
efit in COPD patients. Current anti-inflammatory therapies in 
COPD such as inhaled corticosteroids are not very effective. 
As H. influenzae infection is associated with greater airway 
inflammation in COPD, eradication of H. influenzae may have 
an anti-inflammatory effect. In this review, we focus on two 
interventions that are specifically relevant to Haemophilus 
influenzae infection: vaccination and long-term antibiotics.
vaccination
Because of the significant mortality associated with invasive 
capsulated H. influenzae type b (Hib) disease in infants 
and children, conjugate Hib vaccines were developed that 
induce bactericidal antibodies to the capsular polysaccharide 
polyribitol ribose phosphate. Conjugation of polyribitol ribose 
phosphate to a carrier protein promotes antibody responses 
in infants younger than 2 years.128 After introduction of the 
conjugate Hib vaccine in the United States, the incidence 
of invasive H. influenzae disease has decreased by 99%, 
reaching less than one case per 100,000 children younger 
than 5 years.128 A vaccine for nontypeable H. influenzae 
is attractive because of its role in persistent infection and 
exacerbations in COPD. However, developing such a vaccine 
is likely to prove more challenging than was the case with Hib 
in view of the extensive antigenic variation among membrane 
proteins, lipopolysaccharides, and secreted virulence factors 
displayed by NTHi. Protein P2 is the major immunogenic 
outer membrane protein of NTHi and a target for human bac-
tericidal immune responses. However, the extracellular por-
tions of P2 demonstrate a high degree of sequence variability 
among strains, and antibodies that develop after a COPD 
exacerbation are highly strain-specific and do not prevent 
infection with different strains.109 Point mutations of genes 
coding for P2 or exchange of genes between strains coloniz-
ing the respiratory tract contribute to immune evasion and 
bacterial persistence in the respiratory tract.93,129 Therefore, 
although a P2 vaccine candidate has shown correlates with 
immune protection in animal models,130 it is likely to be a 
poor target in humans.
Protein D is a highly conserved surface lipoprotein 
identified in all strains of H. influenzae. Rats vaccinated 
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with protein D have been shown to clear NTHi more effec-
tively than controls in middle ear and pulmonary clearance 
models.131 In a chinchilla model of otitis media, protein D 
vaccination conferred a 34% protection against development 
of NTHI-induced otitis media.132 Children acquire serum 
antibodies to protein D within the first 2–3 years of life, and 
vaccination with a pneumococcal vaccine conjugated with 
H. influenzae protein D has been shown to induce high cir-
culating levels of antibodies and a 35.5% reduction in otitis 
media caused by NTHi.133 Hawdon et al also demonstrated 
that serum immunoglobulin G antibodies to protein D were 
significantly reduced in adults with COPD when compared 
with healthy, age-matched controls.134 Therefore, on the basis 
of these observations, protein D-containing vaccines may 
be a possible candidate for providing defense against NTHi 
in COPD, but no clinical trials with candidate vaccines are 
yet available.
Oral vaccines
An alternative approach to vaccination has been the develop-
ment of oral vaccines using whole killed NTHi. The mecha-
nisms proposed for protection derived from oral vaccines are 
from rodent models, which demonstrated that they stimulated 
T-lymphocytes derived from gut-associated lymphoid tis-
sue to translocate to bronchus-associated lymphoid tissue, 
thereby stimulating the respiratory epithelial host response.135 
A number of studies using oral vaccinations of whole killed 
NTHi vaccine have been published, and analyzed in a recent 
Cochrane review. The reviewers concluded that oral NTHi 
vaccination in patients with recurrent exacerbations of COPD 
did not significantly reduce either the severity or frequency 
of exacerbations.136
A more recent placebo-controlled study using a new 
NTHi preparation (HI-1640V) in 38 COPD patients showed 
no effect on exacerbation frequency but did report reduc-
tions in mean duration of exacerbations, antibiotic use, and 
sputum cultures.137
The oral administration of bacterial lysates to stimulate 
respiratory immune responses has been used in Europe and 
China for many years. The OM-85 BV bacterial extract, 
a lysate of eight pulmonary pathogens including H.  influenzae, 
is the most commonly studied.138,139 A systematic review of 
published trials of oral immunization with bacterial extracts 
in COPD concluded that the evidence for a reduction in 
exacerbations was inconclusive, but there is some evidence 
for reduction in exacerbation severity and duration.140 To 
date, oral vaccines have not been included in international 
guidelines for COPD.
Antibiotics
A number of studies have investigated the effects of long-
term or pulsed antibiotics in COPD and have reported that 
long-term use of macrolide antibiotics is associated with a 
reduction in exacerbations.141,142 The largest double-blinded, 
randomized, placebo-controlled trial of azithromycin in COPD 
patients demonstrated an increase in time to first exacerbation, 
reduced exacerbation frequency, and made greater improve-
ment in health-related quality of life in the treatment group.143 
Sputum cultures were not carried out, but nasopharyngeal 
swabs were collected in a subset of patients and showed 
reduced colonization in the treatment group, but increased 
incidence of macrolide-resistant organisms. A study of pulsed 
moxifloxacin also showed a reduction in exacerbations and a 
trend toward a reduction in subjects with bacteria cultured in 
sputum in the treatment group.144 Macrolide antibiotics have a 
number of effects apart from their antibacterial effects, includ-
ing anti-inflammatory and antiviral effects.145 Therefore, the 
mechanisms whereby they reduce exacerbations in COPD are 
unclear. In fact, in those studies in which sputum microbiology 
was examined, antibiotic therapy appeared to have no effect 
on prevalence of positive sputum cultures.141,142 Therefore, 
the beneficial effects of macrolides may be mediated by 
mechanisms other than their antibacterial effects. Concerns 
remain regarding the development of antibiotic resistance 
with long-term use of antibiotics and may limit their use as a 
therapeutic strategy in COPD.146
Conclusion
Bacterial infection is common in COPD, both as persistent 
infection in stable patients and in exacerbated patients. 
The most common bacteria detected in COPD patients is 
H. influenzae, and this organism appears to be uniquely adapted 
to exploit structural and immunological abnormalities in the 
lungs in COPD to establish chronic infection. Persistent infec-
tion has been termed colonization, but there is now a wealth 
of evidence that outcomes are worse in COPD patients with 
chronic bacterial infection. Most studies to date have defined 
the presence or absence of H. influenzae, using sputum cul-
tures, but studies using newer molecular diagnostic methods 
suggest that culture underestimates the true prevalence of H. 
influenzae infections. Moreover, with the advent of the abil-
ity to sequence the entire respiratory microbiome, defining 
infection as either the presence or absence of an organism is 
clearly overly simplistic. Increasingly, concepts such as the 
diversity, richness, evenness, and dominance of bacterial popu-
lations will be used to describe the  respiratory  microbiome. 
 Therefore, current thinking regarding the  relationships between 
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H.  influenzae and COPD will change radically on the basis of 
these new concepts. This, in turn, will lead to novel therapeutic 
strategies that may be based on particular microbial patterns in 
the airways in individual COPD patients. Eradication or pre-
vention of H. influenzae infection may lead to improved clinical 
outcomes in COPD, and future therapies may include vac-
cination, antimicrobials, augmentation of immune responses, 
or even manipulation of the respiratory microbiome, as has 
already been trialed in the gastrointestinal tract. In addition, 
the recognition of the relationship between respiratory virus 
infection and H. influenzae, coupled with the development of 
antiviral agents, offers the possibility of reducing the burden 
of bacterial infection by treating or preventing respiratory 
virus infections. Current therapies for COPD (inhaled bron-
chodilators and corticosteroids) have only modest effects and 
do not prevent disease progression. New therapies targeting 
H. influenzae offer a novel therapeutic strategy that provides 
the possibility of improving clinical outcomes and modifying 
disease activity in COPD.
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